Danaher delivered strong Q4 2025 results, with adjusted EPS rising to $2.23 and revenue hitting $6.8 billion. Net income came in at $1.2 billion, driven by strength in its Bioprocessing, Diagnostics, and Life Sciences businesses.

Danaher delivered a strong Q3 with higher-than-expected revenue and earnings, driven by bioprocessing momentum and Cepheid's respiratory business.

Danaher posted strong Q2 2025 results driven by Bioprocessing growth and disciplined cost management, despite a fluid macro environment.

Danaher’s Q1 2025 performance exceeded expectations, with net income reaching nearly $1 billion, flat core revenue, and continued strength in bioprocessing and diagnostics segments.

Danaher Corporation reported a 2.0% increase in revenues to $6.5 billion for the fourth quarter of 2024, with a 1.0% increase in non-GAAP core revenue. Net earnings were $1.1 billion, or $1.49 per diluted common share, while non-GAAP adjusted diluted net earnings per common share were $2.14. The company's operating cash flow was $2.0 billion, and non-GAAP free cash flow was $1.5 billion.

Danaher reported strong third quarter results with better-than-expected revenue growth, driven by positive momentum in the bioprocessing business and market share gains in molecular testing by Cepheid. Revenues increased by 3.0% year-over-year, and non-GAAP core revenue increased by 0.5%.

Danaher Corporation reported a decrease in revenue by 3.0% year-over-year to $5.7 billion, with a non-GAAP core revenue decrease of 3.5%. Net earnings were $907 million, or $1.22 per diluted common share, while non-GAAP adjusted diluted net earnings per common share were $1.72. The company's operating cash flow was $1.4 billion, and non-GAAP free cash flow was $1.1 billion.

Danaher Corporation announced its Q1 2024 results, with net earnings of $1.1 billion, or $1.45 per diluted common share. Non-GAAP adjusted diluted net earnings per common share were $1.92. Revenues decreased 2.5% year-over-year to $5.8 billion, and non-GAAP core revenue decreased 4.0%. Operating cash flow was $1.7 billion, and non-GAAP free cash flow was $1.4 billion.

Danaher reported fourth quarter 2023 results with revenues decreasing 10.0% year-over-year to $6.4 billion. Net earnings were $1.1 billion, or $1.50 per diluted common share, while non-GAAP adjusted diluted net earnings per common share were $2.09. The company exceeded margin and cash flow expectations despite a dynamic market environment, with respiratory revenue at Cepheid leading the way.

Danaher Corporation reported a 10.5% year-over-year decrease in revenues to $6.9 billion. Net earnings were $1.1 billion, or $1.51 per diluted common share. Non-GAAP adjusted diluted net earnings per common share were $2.02. The company's third quarter results include the operations of Veralto Corporation, which was spun-off on September 30, 2023.

Danaher reported Q2 2023 results with revenues decreasing 7.5% year-over-year to $7.2 billion. Net earnings were $1.1 billion, or $1.49 per diluted common share, while non-GAAP adjusted diluted net earnings per common share were $2.05. The company anticipates non-GAAP base business core revenue will be down low-single digits year-over-year for Q3 2023 and up low-single digits year-over-year for full year 2023.

Danaher reported a decrease in revenue by 7.0% year-over-year to $7.2 billion, with a 4.0% non-GAAP core revenue decrease. Net earnings were $1.4 billion, or $1.94 per diluted common share, while non-GAAP adjusted diluted net earnings per common share were $2.36. The company's base business core revenue grew by 6.0%.

Danaher Corporation reported a 2.5% increase in revenue to $8.4 billion for Q4 2022, with net earnings reaching $2.2 billion, or $2.99 per diluted share, a 25% increase year-over-year. Non-GAAP core revenue growth was 7.5%.

Danaher Corporation announced its Q3 2022 results, with revenues increasing by 6.0% year-over-year to $7.7 billion. Net earnings were $1.6 billion, or $2.10 per diluted common share, a 36.0% increase. Non-GAAP adjusted diluted net earnings per common share were $2.56, a 7.0% increase. Non-GAAP core revenue growth was 10.0%, including 8.5% non-GAAP base business core revenue growth. Operating cash flow was $2.0 billion and non-GAAP free cash flow was $1.7 billion.

Danaher Corporation announced its second quarter 2022 results, with net earnings of $1.7 billion, or $2.25 per diluted common share. Revenues increased 7.5% year-over-year to $7.8 billion. Non-GAAP core revenue growth was 9.5%, including 8.0% non-GAAP base business core revenue growth.

Danaher Corporation reported a strong start to the year, exceeding initial expectations with double-digit core revenue growth. The company's Q1 results showed a 12.0% increase in revenues year-over-year, reaching $7.7 billion, and a 9.5% increase in non-GAAP adjusted diluted net earnings per common share.

Danaher Corporation reported a strong fourth quarter and full year 2021. For the quarter ended December 31, 2021, revenues increased 20.5% year-over-year to $8.1 billion, with 19.5% non-GAAP core revenue growth. Net earnings were $1.8 billion, or $2.39 per diluted common share. Non-GAAP adjusted diluted net earnings per common share were $2.69.

Danaher Corporation reported a strong third quarter in 2021, with revenues increasing by 23.0% year-over-year to $7.2 billion and non-GAAP core revenue growth of 20.5%. Net earnings were $1.2 billion, or $1.54 per diluted common share, a 33.0% increase year-over-year. Non-GAAP adjusted diluted net earnings per common share were $2.39, representing a 39.0% increase over the comparable 2020 period.

Danaher Corporation announced strong second quarter 2021 results, with a 36.5% increase in revenues to $7.2 billion and net earnings of $1.7 billion, or $2.28 per diluted common share, representing an 84.0% year-over-year increase. Non-GAAP adjusted diluted net earnings per common share were $2.46, a 71.0% increase over the comparable 2020 period. The company anticipates non-GAAP core revenue growth in the mid- to high-teens percent range for the third quarter and approximately 20% for the full year 2021.

Danaher reported a strong start to 2021 with better-than-expected Q1 results. Revenues increased by 58.0% year-over-year to $6.9 billion, with a 30.0% non-GAAP core revenue growth. Net earnings were $1.7 billion, or $2.29 per diluted common share, a 182.5% increase year-over-year. The company anticipates strong non-GAAP core revenue growth for Q2 and the full year 2021.

Danaher Corporation reported a strong fourth quarter and full year 2020, marked by a 39.0% increase in revenue for the quarter, driven by 15.5% non-GAAP core revenue growth including Cytiva. Net earnings for the quarter were $1.2 billion, or $1.66 per diluted common share, representing a 55.0% year-over-year increase. The company's non-GAAP adjusted diluted net earnings per common share for the quarter were $2.08, a 62.5% increase over the previous year.

Danaher Corporation announced strong Q3 2020 results, with a 34.5% increase in revenues to $5.9 billion and a 62.0% increase in non-GAAP adjusted diluted net earnings per common share to $1.72. The company also saw a 93.0% increase in operating cash flow and a 110.0% increase in non-GAAP free cash flow.

Danaher Corporation reported a strong second quarter with a 19.0% increase in revenues to $5.3 billion and a 38.0% increase in net earnings per share to $1.24. Non-GAAP adjusted diluted net earnings per share were $1.44, a 32.0% increase. The company's performance was driven by its team's commitment to the Danaher Business System and its portfolio of businesses.

Danaher Corporation reported a 3.0% increase in revenues to $4.3 billion for the first quarter of 2020, with net earnings of $595.1 million, or $0.81 per diluted common share. Non-GAAP adjusted diluted net earnings per common share were $1.05, and core revenue growth was 4.5%. The company also closed its acquisition of the GE Biopharma business, now called Cytiva, on March 31.

Danaher Corporation reported a 5.5% increase in revenue to $4.9 billion for Q4 2019, with net earnings of $792.9 million, or $1.07 per diluted share. Non-GAAP adjusted diluted net earnings per share were $1.28, representing a 12.5% increase year-over-year. The company achieved 6.0% core revenue growth.